{"ok":true,"entity":{"id":"biogen","name":"Biogen Inc.","entityType":"company","officialName":"Biogen Inc.","canonicalName":"Biogen Inc.","displayName":"Biogen Inc.","category":"神経・免疫・希少疾患領域のバイオ医薬品企業","shortDescription":"Biogen Inc.は米国マサチューセッツ州ケンブリッジに本社を置く、1978年創業のバイオ医薬品企業です（デラウェア州法人）。神経、免疫、希少疾患の領域で治療薬を開発し、エーザイとアルツハイマー病治療薬LEQEMBIを共同で商業化しています。2026年5月14日にApellis Pharmaceuticalsの買収を完了しました（2026年10月時点）。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.biogen.com/","updatedAt":"2026-10-20T07:08:03.177Z","secondaryClusters":[],"alias":["Biogen","Biogen Idec","バイオジェン"],"searchKeywords":["バイオジェン","Biogen","Biogen Idec","レケンビ","LEQEMBI","レカネマブ","アルツハイマー病","多発性硬化症","バイオ医薬品","Apellis"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}